US appeals court upholds patent for Lilly PMS drug
Posted on: Wednesday, 13 July 2005, 10:37 CDT
WASHINGTON (Reuters) - A U.S. appeals court on Wednesday upheld Eli Lilly and Co.'s patent for its premenstrual drug Sarafem, rejecting a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd .
Teva had argued the patent, which covers the use of fluoxetine to treat premenstrual syndrome (PMS), was invalid because it was for something that was "obvious."
The U.S. Court of Appeals for the Federal Circuit affirmed a lower court ruling that found Teva had infringed the patent.
Source: REUTERS
Related Articles
- Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision
- acardo Wins Patent Case, as Catalina Drops Patent Infringement Charges
- German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
- Pixelplus Announces MagnaChip's Complete Withdrawal of Its Appeals on the Disputed Process Patents in Korean Patent Court
- German Appeals Court Rules in Favor of AGA Medical in Patent Infringement Lawsuit Against Occlutech
- Teva Comments on Paragraph IV Filing for COPAXONE(R)
- Teva Receives Court Ruling Awarding Exclusivity for Generic Risperdal(R)
- Teva Announces Court of Appeals Denies Novartis' Emergency Motion on Generic Famvir(R)
- Eli Lilly and Company Comments on Recent Court Rulings Regarding Zyprexa(R) Patents
- Supreme Court to Hear eBay Patent Dispute Case
Rating: 3.0 / 5 (9 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds